Skip to content

Study · Observational study · 2026

8 results

Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: A prospective study.

Pérez-Pevida B, Santana Santana M, Liaño Arriola C, Maldonado A, Clérigo B, Ruiz C, Higueruela C, Ballesteros-Pomar MD, Bretón Lesmes I, Moreira Rodríguez M

Clinical nutrition ESPEN1 Aug 2026

PMID42542297 (opens in a new tab)DOI10.1016/j.clnesp.2026.105005 (opens in a new tab)PepBankPUB-42542297
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

Background and aimsRecent randomised controlled trials have demonstrated the efficacy of tirzepatide in inducing weight loss among adults with overweight or obesity, irrespective of diabetes mellitus status. However, evidence from real-world settings remains limited. This study aimed to evaluate the effectiveness and safety of tirzepatide for weight management in routine clinical practice.MethodsThis prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions. The primary outcomes were changes in body weight and body composition after 6 months of treatment. Secondary assessments included anthropometric and cardiometabolic parameters, quality of life, and tolerability.ResultsThe median tirzepatide dose at 6 months was 7.5 mg. At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline. A total of 95.35% of participants achieved at least 5% weight loss, and 60.47% achieved ≥15%. Significant improvements were observed in glycaemic and lipid profiles, with enhancements in health-related quality of life and a favourable tolerability profile. The dropout rate was 3.7%.ConclusionsThis prospective real-world study confirms the effectiveness and safety of tirzepatide for weight management, even at maintenance doses lower than the approved dose, and supports findings from randomised clinical trials.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity in routine care, tirzepatide reduced mean body weight by 17.21% from baseline at 6 months.

    In plain wordsIn adults with obesity in routine care, people lost on average 17.21% of their weight after 6 months on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight reduction at 6 months
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Measurements

    Mean body weight reduction
    18.04 kg
    6 months
    Body weight decrease from baseline
    17.21%
    6 months

    Source sentences

    Summary
    At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline.
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity in routine care, glycaemic parameters improved significantly during tirzepatide treatment.

    In plain wordsIn adults with obesity in routine care, blood sugar measures improved on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedGlycaemic profile
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant improvements were observed in glycaemic and lipid profiles
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity in routine care, lipid parameters improved significantly during tirzepatide treatment.

    In plain wordsIn adults with obesity in routine care, blood fat measures improved on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedLipid profile
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant improvements were observed in glycaemic and lipid profiles
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.
  4. 04HumanObservational studyEfficacy outcome

    In adults with obesity in routine care, health-related quality of life improved during tirzepatide treatment.

    In plain wordsIn adults with obesity in routine care, quality of life improved on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHealth-related quality of life
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Quality of life · Whole body
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    with enhancements in health-related quality of life and a favourable tolerability profile.
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.
  5. 05HumanObservational studySafety outcome

    In adults with obesity in routine care, tirzepatide had a favourable tolerability profile.

    In plain wordsIn adults with obesity in routine care, tirzepatide was described as well tolerated.

    Peptide
    Tirzepatide
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    a favourable tolerability profile.
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.
  6. 06HumanObservational studyEfficacy outcome

    In adults with obesity in routine care, 95.35% of participants achieved at least 5% weight loss at 6 months of tirzepatide.

    In plain wordsIn adults with obesity in routine care, nearly all people lost at least 5% of their weight on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProportion with at least 5% weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Measurements

    Proportion with at least 5% weight loss
    95.35%
    6 months

    Source sentences

    Summary
    A total of 95.35% of participants achieved at least 5% weight loss
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.
  7. 07HumanObservational studyEfficacy outcome

    In adults with obesity in routine care, 60.47% of participants achieved at least 15% weight loss at 6 months of tirzepatide.

    In plain wordsIn adults with obesity in routine care, more than half of people lost at least 15% of their weight on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseProportion with at least 15% weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Measurements

    Proportion with at least 15% weight loss
    60.47%
    6 months

    Source sentences

    Summary
    60.47% achieved ≥15%.
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.
  8. 08HumanObservational studySafety outcome

    In adults with obesity in routine care, the dropout rate during tirzepatide treatment was 3.7%.

    In plain wordsIn adults with obesity in routine care, 3.7% of people stopped taking part during tirzepatide treatment.

    Peptide
    Tirzepatide
    Outcome
    Not applicableDropout rate
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    median 7.5 mg at 6 months · 6 monthsAs given in this study (human).

    Measurements

    Dropout rate
    3.7%
    6 months

    Source sentences

    Summary
    The dropout rate was 3.7%.
    2 context sentences
    Summary · context
    This prospective, longitudinal, observational study assessed the effects of tirzepatide in 107 participants with a body mass index of ≥30 kg/m2 or ≥27 kg/m2 and at least one weight-related comorbidity in real-world conditions.
    Summary · context
    The primary outcomes were changes in body weight and body composition after 6 months of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.